{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T21:59:15Z","timestamp":1720821555055},"reference-count":38,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.3892\/or.2015.4454","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T08:55:14Z","timestamp":1448528114000},"page":"1417-1424","source":"Crossref","is-referenced-by-count":5,"title":["Selective and augmented \u03b2-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer"],"prefix":"10.3892","volume":"35","author":[{"given":"LONGXIN","family":"WANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIE","family":"DONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MING","family":"WEI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIHONG","family":"WEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIANPING","family":"GAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHENGYU","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIJUN","family":"QIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"key":"key20180107210651_b1-or-35-03-1417","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.20388","article-title":"Gene therapy for prostate cancer: Current strategies and new cell-based approaches","volume":"66","author":"MacRae","year":"2006","journal-title":"Prostate"},{"key":"key20180107210651_b2-or-35-03-1417","first-page":"551","article-title":"Prostate cancer therapy: Standard management, new options and experimental approaches","volume":"25","author":"Trojan","year":"2005","journal-title":"Anticancer Res"},{"key":"key20180107210651_b3-or-35-03-1417","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.mou.0000165552.79416.11","article-title":"Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer","volume":"15","author":"Ward","year":"2005","journal-title":"Curr Opin Urol"},{"key":"key20180107210651_b4-or-35-03-1417","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.mou.0000165553.17534.e3","article-title":"Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer","volume":"15","author":"Ward","year":"2005","journal-title":"Curr Opin Urol"},{"key":"key20180107210651_b5-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2174\/1381612023394485","article-title":"Beta-glucuronidase-mediated drug release","volume":"8","author":"de Graaf","year":"2002","journal-title":"Curr Pharm Des"},{"key":"key20180107210651_b6-or-35-03-1417","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1075>3.0.CO;2-L","article-title":"Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate","volume":"91","author":"Houba","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180107210651_b7-or-35-03-1417","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1054\/bjoc.2000.1640","article-title":"A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: Distribution and efficacy in experimental human ovarian cancer","volume":"84","author":"Houba","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180107210651_b8-or-35-03-1417","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1566523023347733","article-title":"Influence of the bystander effect on HSV-tk\/GCV gene therapy. A review","volume":"2","author":"van Dillen","year":"2002","journal-title":"Curr Gene Ther"},{"key":"key20180107210651_b9-or-35-03-1417","first-page":"3989","article-title":"Bystander effect in herpes simplex virus-thymidine kinase\/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication","volume":"60","author":"Mesnil","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107210651_b10-or-35-03-1417","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1521-2254(199911\/12)1:6<407::AID-JGM71>3.0.CO;2-Q","article-title":"Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy","volume":"1","author":"Fonseca","year":"1999","journal-title":"J Gene Med"},{"key":"key20180107210651_b11-or-35-03-1417","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bjc.6600143","article-title":"A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug","volume":"86","author":"de Graaf","year":"2002","journal-title":"Br J Cancer"},{"key":"key20180107210651_b12-or-35-03-1417","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1021\/jm0493865","article-title":"Beta-glucuronidase-cleavable prodrugs of O6-benzylguanine and O6-benzyl-2\u2032-deoxyguanosine","volume":"48","author":"Wei","year":"2005","journal-title":"J Med Chem"},{"key":"key20180107210651_b13-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/bjc.1998.729","article-title":"The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts","volume":"78","author":"Houba","year":"1998","journal-title":"Br J Cancer"},{"key":"key20180107210651_b14-or-35-03-1417","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s002100000260","article-title":"Expression and function of beta-glucuronidase in pancreatic cancer: Potential role in drug targeting","volume":"362","author":"Sperker","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key20180107210651_b15-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.gt.3301972","article-title":"In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia","volume":"10","author":"Park","year":"2003","journal-title":"Gene Ther"},{"key":"key20180107210651_b16-or-35-03-1417","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.cgt.7700344","article-title":"Prostate-specific targeting using PSA promoter-based lentiviral vectors","volume":"8","author":"Yu","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"key20180107210651_b17-or-35-03-1417","first-page":"3620","article-title":"Targeted expression of green fluorescent protein\/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res"},{"key":"key20180107210651_b18-or-35-03-1417","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/10915360050138611","article-title":"Suicide gene therapy for urogenital cancer: Current outcome and prospects","volume":"4","author":"Nasu","year":"2000","journal-title":"Mol Urol"},{"key":"key20180107210651_b19-or-35-03-1417","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00268-002-4053-5","article-title":"Current progress in suicide gene therapy for cancer","volume":"26","author":"Yazawa","year":"2002","journal-title":"World J Surg"},{"key":"key20180107210651_b20-or-35-03-1417","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3816\/CLC.2005.n.002","article-title":"Replacement and suicide gene therapy for targeted treatment of lung cancer","volume":"6","author":"Poulsen","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"key20180107210651_b21-or-35-03-1417","first-page":"495","article-title":"Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects","volume":"18","author":"Nicholas","year":"2003","journal-title":"Histol histopathol"},{"key":"key20180107210651_b22-or-35-03-1417","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1566523033347426","article-title":"Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene\/ganciclovir system: Fifteen years of application","volume":"3","author":"Fillat","year":"2003","journal-title":"Curr Gene Ther"},{"key":"key20180107210651_b23-or-35-03-1417","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1566523052997523","article-title":"In situ gene therapy for prostate cancer","volume":"5","author":"Satoh","year":"2005","journal-title":"Curr Gene Ther"},{"key":"key20180107210651_b24-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0022-5347(05)67534-9","article-title":"Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer","volume":"163","author":"Shalev","year":"2000","journal-title":"J Urol"},{"key":"key20180107210651_b25-or-35-03-1417","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/108497803322285099","article-title":"Chimeric TNT-3\/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT)","volume":"18","author":"Biela","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"key20180107210651_b26-or-35-03-1417","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V92.1.184.413k26_184_190","article-title":"Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy","volume":"92","author":"Haisma","year":"1998","journal-title":"Blood"},{"key":"key20180107210651_b27-or-35-03-1417","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cgt.7700874","article-title":"Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity","volume":"13","author":"Kaliberov","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"key20180107210651_b28-or-35-03-1417","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.cgt.7700807","article-title":"Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase\/CB1954 is enhanced by high-level coexpression of heat shock protein 70","volume":"12","author":"Djeha","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"key20180107210651_b29-or-35-03-1417","first-page":"6805","article-title":"Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate","volume":"61","author":"Miki","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107210651_b30-or-35-03-1417","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1155\/S1110724303209098","article-title":"Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy)","volume":"2003","author":"Denny","year":"2003","journal-title":"J Biomed Biotechnol"},{"key":"key20180107210651_b31-or-35-03-1417","doi-asserted-by":"crossref","first-page":"723","DOI":"10.18388\/abp.2004_3557","article-title":"CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase\/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter","volume":"51","author":"Dabrowska","year":"2004","journal-title":"Acta Biochim Pol"},{"key":"key20180107210651_b32-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1349-7006.2002.tb01218.x","article-title":"Development of gene therapy using prostate-specific membrane antigen promoter\/enhancer with Cre Recombinase\/LoxP system for prostate cancer cells under androgen ablation condition","volume":"93","author":"Ikegami","year":"2002","journal-title":"Jpn J Cancer Res"},{"key":"key20180107210651_b33-or-35-03-1417","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.gt.3302580","article-title":"Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells","volume":"12","author":"Peng","year":"2005","journal-title":"Gene Ther"},{"key":"key20180107210651_b34-or-35-03-1417","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.gt.3301618","article-title":"Tumor-specific transcriptional targeting of suicide gene therapy","volume":"9","author":"Qiao","year":"2002","journal-title":"Gene Ther"},{"key":"key20180107210651_b35-or-35-03-1417","first-page":"6158","article-title":"Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase\/5-fluorocytosine enhanced by the cre\/loxP system in the orthotopic gastric carcinoma model","volume":"61","author":"Ueda","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107210651_b36-or-35-03-1417","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/mthe.2001.0273","article-title":"Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system","volume":"3","author":"Koch","year":"2001","journal-title":"Mol Ther"},{"key":"key20180107210651_b37-or-35-03-1417","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/1043034041361271","article-title":"Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression","volume":"15","author":"Ray","year":"2004","journal-title":"Hum Gene Ther"},{"key":"key20180107210651_b38-or-35-03-1417","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11248-004-2836-1","article-title":"Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy","volume":"14","author":"Iyer","year":"2005","journal-title":"Transgenic Res"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4454\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T22:58:04Z","timestamp":1599865084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,11,26]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3892\/or.2015.4454"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4454","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]}}}